Jump to content

Rifampicin/isoniazid/pyrazinamide

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by WildCation (talk | contribs) at 15:20, 12 May 2015 (The SMILES and InChIs referred to just Rifampicin rather than this combination drug, so I have removed them.). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Rifampicin/isoniazid/pyrazinamide
Combination of
RifampicinRifamycin antibiotic
IsoniazidFirst-line anti-tuberculosis medication
PyrazinamideAnti-tuberculosis medication
Clinical data
Trade namesRifater, Trifazid
AHFS/Drugs.comFDA Professional Drug Information
Pregnancy
category
  • C
Routes of
administration		Oral
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
PubChem CID
  (verify)

Rifampicin/isoniazid/pyrazinamide (trade name Rifater) is a fixed dose combination tablet manufactured by Aventis used in the treatment of tuberculosis. Each tablet contains 120 mg rifampicin, 50 mg isoniazid and 300 mg pyrazinamide. It is used in initial treatment of tuberculosis, typically for the first two months.[1][2]

Rifater is contraindicated in children with a body weight of under 40 kg.[2]

The purpose of the fixed dose combination is to make it easier for patients to take their medication; but also to ensure that if patients forget to take one or two of their drugs, they do not then develop resistance to the remaining drugs.

See also

References

  1. ^ Drugs.com: Rifater
  2. ^ a b Jasek, W, ed. (2007). Austria-Codex (in German) (2007/2008 ed.). Vienna: Österreichischer Apothekerverlag. ISBN 978-3-85200-181-4.


Stub icon

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Rifampicin/isoniazid/pyrazinamide&oldid=662012045"